TGA Logo

The site you are about to enter is intended
for US healthcare professionals only.

VISIT PATIENT WEBSITE
Request an Ionis Specialist | TGAware Skip to main content
TGAware logo - light version
Request Ionis Specialist

Subscribe to TGAware.com

To help better manage patients with sHTG, sign up and join a community of healthcare professionals receiving the latest resources and updates about severe hypertriglyceridemia (sHTG).

Intended for US healthcare professionals only.

*

Required fields.

By clicking the “Submit” button, I agree that Ionis and its subsidiaries may use the information I’m submitting to contact me with information about familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (sHTG), and related therapies. I understand that all personal information I’ve submitted will be used in accordance with Ionis’ privacy policy, and I agree to the terms of use. To manage your marketing preferences, go to Your Privacy Choices.

Main navigation

  • Unmet need of sHTG

    Unmet need of sHTG

    Arrow

    sHTG demands urgent action to reduce potentially
life-threatening risks such as acute pancreatitis and atherosclerotic cardiovascular disease. However, underestimation of sHTG and limitations of current treatments continue to pose challenges for effective management.

    Jump to:
    About sHTG Arrow Causes Arrow Prevalence and postprandial spikes Arrow Existing treatment approaches Arrow
  • Associated risks of sHTG

    Associated risks of sHTG

    Arrow

    In sHTG, triglyceride levels and lipoprotein composition are closely linked to the risk of acute pancreatitis (AP) and atherosclerotic cardiovascular disease (ASCVD). Understanding how lipoproteins contribute to these risks can help you get a better picture of your patients' risk profile.

    Jump to:
    The role of lipoproteins Arrow AP risk Arrow ASCVD risk Arrow Other risks Arrow
  • Identifying sHTG

    Identifying sHTG

    Arrow

    Early identification is essential to effective management of sHTG. Timely intervention can help reduce serious risks such as acute pancreatitis (AP). Explore these patient profiles to see how sHTG may appear in your practice.

  • Expert recommendations

    Expert recommendations

    Arrow

    Expert organizations, including the American Heart Association, American College of Cardiology, National Lipid Association, and Endocrine Society, emphasize the importance of lowering fasting triglyceride levels that are >500 mg/dL to reduce associated risks. Achieving this requires carefully addressing related comorbidities.

    Jump to:
    Expert guidance Arrow Metabolic considerations Arrow
  • FCS

    Familial chylomicronemia syndrome (FCS)

    Arrow

    FCS is a genetic form of severe hypertriglyceridemia (sHTG) caused by mutations in the gene encoding lipoprotein lipase (LPL) or by mutations in genes encoding proteins necessary for LPL function. This condition manifests in physical complications such as lipemia retinalis, eruptive xanthomas, and an increased risk of potentially life-threatening acute pancreatitis (AP). Read about identifying, diagnosing, and managing FCS.

    Jump to:
    About FCS Arrow Diagnosing FCS Arrow Diagnostic scoring tools Arrow Genetic testing Arrow FCS patient case Arrow Managing FCS Arrow
  • Resources

    Resources

    Arrow

    Access publications, videos, and downloadable content for severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS).

Request Ionis Specialist

Hear from an Ionis Clinical 
Account Specialist  

Fill out the form below to request to connect with an Ionis Clinical Account Specialist and receive the latest resources and updates about severe hypertriglyceridemia (sHTG).

Intended for US healthcare professionals only.

*Required fields.

By clicking the “Submit” button, I agree that Ionis and its subsidiaries may use the information I’m submitting to contact me with information about familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (sHTG), and related therapies. I understand that all personal information I’ve submitted will be used in accordance with Ionis’ privacy policy, and I agree to the terms of use. To manage your marketing preferences, go to Your Privacy Choices.

TGAware logo - dark version Ionis logo

©2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.

All rights reserved.

US-SHTG-2500014 v2.0 01/2026

This site is intended for US healthcare professionals only.

Footer

  • Terms of Use
  • Privacy Policy
  • Consumer Health Data Privacy Policy
  • Your Privacy Choices
  • Site Map

©2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.

All rights reserved.

US-SHTG-2500014 v2.0 01/2026

This site is intended for US healthcare professionals only.

Footer

  • Terms of Use
  • Privacy Policy
  • Consumer Health Data Privacy Policy
  • Your Privacy Choices
  • Site Map